Sinocelltech Group Ltd Total Liabilities
Sinocelltech Group Ltd total liabilities. Based on the latest financial reports, Sinocelltech Group Ltd (688520) has total liabilities worth CN¥4.49 Billion CNY (≈ $657.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sinocelltech Group Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sinocelltech Group Ltd (2016–2024)
Total liabilities of Sinocelltech Group Ltd from 2016 to 2024. This chart illustrates how Sinocelltech Group Ltd's total liabilities have evolved over time, based on quarterly financial data.
Sinocelltech Group Ltd Competitors by Total Liabilities
The table below lists competitors of Sinocelltech Group Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dno ASA
OL:DNO
|
Norway | Nkr4.89 Billion |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
China | CN¥1.39 Billion |
|
Skyward Specialty Insurance Group, Inc. Common Stock
NASDAQ:SKWD
|
USA | $5.32 Billion |
|
Y.H. Dimri Construction & Development Ltd
TA:DIMRI
|
Israel | ILA6.01 Billion |
|
Shanghai Zhenhua Heavy Industries Co Ltd A
SHG:600320
|
China | CN¥62.09 Billion |
|
Altius Minerals Corporation
TO:ALS
|
Canada | CA$132.97 Million |
|
Formula Systems 1985 Ltd ADR
NASDAQ:FORTY
|
USA | $1.75 Billion |
|
McGraw Hill, Inc.
NYSE:MH
|
USA | $4.76 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Sinocelltech Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Sinocelltech Group Ltd.
Liquidity & Leverage Metrics
Sinocelltech Group Ltd Total Liabilities Ratios Explained
Sinocelltech Group Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinocelltech Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual total liabilities of Sinocelltech Group Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.15 Billion ≈ $460.81 Million |
-5.27% |
| 2023-12-31 | CN¥3.32 Billion ≈ $486.46 Million |
+11.63% |
| 2022-12-31 | CN¥2.98 Billion ≈ $435.78 Million |
+85.64% |
| 2021-12-31 | CN¥1.60 Billion ≈ $234.74 Million |
+49.21% |
| 2020-12-31 | CN¥1.08 Billion ≈ $157.33 Million |
+39.02% |
| 2019-12-31 | CN¥773.39 Million ≈ $113.17 Million |
+37.22% |
| 2018-12-31 | CN¥563.60 Million ≈ $82.47 Million |
+76.62% |
| 2017-12-31 | CN¥319.10 Million ≈ $46.69 Million |
-6.50% |
| 2016-12-31 | CN¥341.30 Million ≈ $49.94 Million |
-- |
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more